uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

uniQure (NASDAQ:QURE) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04, FiscalAI reports. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $6.17 million.

Here are the key takeaways from uniQure’s conference call:

• The FDA accepted uniQure’s BLA for AMT-130 and granted Priority Review, setting a target decision date of May 1, 2027; the U.K. regulator also validated the company’s marketing application. The FDA is tentatively planning an advisory committee discussion, but approval is not assured.
• Management highlighted prior AMT-130 results showing a reported 75% slowing of disease progression on cUHDRS and 60% on Total Functional Capacity at 36 months versus a matched external control. The company also cited follow-up through 48 months, while noting the evidence comes from a small number of patients.
• The planned confirmatory study will enroll about 200 patients, randomize them 2:1 to AMT-130 or standard of care, and assess TFC at 36 months; screening is expected to begin by year-end. UniQure says it is preparing to have the study well underway by a potential approval, while planning for possible control-arm dropouts and global recruitment.
• Launch preparations are focused on specialist centers, with the company targeting more than 15 operational centers at launch but not yet specifying patient capacity. Management identified center readiness, institutional approvals and payer access as potential factors affecting how quickly patients could receive treatment.
• Cash, cash equivalents and investments totaled $768.4 million at quarter-end, and management expects funding to last into 2030. SG&A increased year over year amid hiring and launch preparations; separately, the company expects updated AMT-260 epilepsy and AMT-191 Fabry data in the first half of 2027.

uniQure Price Performance

QURE stock traded down $2.08 during mid-day trading on Thursday, hitting $20.95. The stock had a trading volume of 1,950,311 shares, compared to its average volume of 2,412,396. The firm has a fifty day simple moving average of $33.01 and a 200 day simple moving average of $29.69. The firm has a market capitalization of $1.45 billion, a P/E ratio of -5.22 and a beta of 1.14. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a 52 week low of $8.73 and a 52 week high of $51.72.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA granted priority review to uniQure’s BLA for AMT-130, its Huntington’s disease gene therapy, with a target decision date of May 1, 2027. This advances the application toward a decision, though approval is not assured. Company update
• Neutral Sentiment: Q3 loss narrowed year over year to $0.88 per share, but revenue of $5.2 million came in below consensus estimates. EPS comparisons varied by analyst source: the result beat some estimates and missed others. Q3 results
• Negative Sentiment: Coverage highlighted a proposed confirmatory study of roughly 200 patients for AMT-130. The study adds execution and funding considerations, while the FDA review and May 2027 decision date leave a lengthy period of uncertainty for investors. Confirmatory study and review date

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings upgraded shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Barclays downgraded shares of uniQure from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $60.00 to $28.00 in a research report on Monday, October 5th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research note on Wednesday, July 29th. Finally, UBS Group started coverage on uniQure in a research report on Thursday, October 15th. They set a “buy” rating and a $48.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.83.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.